Retatrutide Phase 3: 28.7% Weight Loss, Osteoarthritis Relief, and a Safety Signal Worth Watching

Retatrutide just delivered Phase 3 results that redefine what’s possible in pharmaceutical weight loss—and raised new questions about tolerability.

Eli Lilly’s retatrutide just delivered what may be the most impressive weight loss number a Phase 3 trial has ever produced—and buried inside the results is a safety signal that deserves more attention than it’s getting.

The TRIUMPH-4 trial enrolled adults with obesity or overweight and knee osteoarthritis. At 68 weeks, participants taking retatrutide 12 mg lost an average of 28.7% of their body weight—roughly 71 pounds. For context, tirzepatide (Mounjaro/Zepbound) produced approximately 22% weight loss in its registrational trials, and semaglutide (Wegovy) produced approximately 15%. Retatrutide is playing in a different league. (Eli Lilly investor release)

But TRIUMPH-4 wasn’t just a weight loss trial. It was designed to test whether that weight loss translates into functional improvement in a specific disease—and the answer was unambiguous. WOMAC pain scores dropped by up to 75.8%, with more than 1 in 8 retatrutide-treated patients reporting complete freedom from knee pain at end of trial. (BioSpace)

That’s a compelling story: a weight loss drug that doesn’t just shrink waistlines but demonstrably improves joint function and eliminates pain. If the remaining Phase 3 data looks similar, retatrutide will likely be the most effective obesity drug ever approved.

The Triple Agonist Mechanism

Retatrutide is a first-in-class triple agonist—it activates GLP-1, GIP, and glucagon receptors simultaneously. That’s one more receptor than tirzepatide (which hits GLP-1 and GIP) and two more than semaglutide (GLP-1 only).

The glucagon receptor activation is what makes this mechanistically distinct. Glucagon drives hepatic glucose output and promotes lipolysis—the breakdown of stored fat. In theory, adding glucagon agonism to GLP-1’s appetite suppression and GIP’s insulin sensitization creates a triple metabolic hit: eat less, burn more fat, improve metabolic health on multiple axes simultaneously.

The Phase 2 data, published in the New England Journal of Medicine, showed weight loss of up to 24.2% at 48 weeks—numbers that prompted Eli Lilly to pursue one of the largest Phase 3 programs in obesity drug development. TRIUMPH-4 is the first of those Phase 3 trials to report. Seven more readouts are expected in 2026, including studies in type 2 diabetes and trials testing maintenance dosing strategies.

The Safety Signal

Here’s the part that deserves a closer read.

Discontinuation rates due to adverse events were 12.2% at the 9 mg dose and 18.2% at the 12 mg dose, compared to 4.0% on placebo. Nearly one in five patients on the highest dose stopped treatment because of side effects. (FierceBiotech)

Lilly notes that these discontinuation rates “were highly correlated with baseline BMI and included discontinuations for perceived excessive weight loss.” That last phrase—”perceived excessive weight loss”—is doing a lot of work. It means some patients lost weight so rapidly that either they or their physicians decided to stop treatment, not because of a traditional adverse event but because the drug was working too well.

Whether you file “too much weight loss” as a safety signal or an efficacy problem depends on your perspective. From a clinical standpoint, excessive or too-rapid weight loss carries real risks: gallstone formation, muscle mass loss, nutritional deficiencies, and metabolic adaptation that can make weight regain more aggressive. From a regulatory standpoint, an 18% discontinuation rate is high enough that the FDA will scrutinize it closely.

The GI side effects were largely consistent with the GLP-1 class—nausea, vomiting, diarrhea—though the addition of glucagon agonism introduces the theoretical possibility of hepatic effects that will need monitoring in longer-term data.

How Retatrutide Reshapes the Obesity Drug Landscape

Retatrutide’s TRIUMPH-4 results land in a GLP-1 and obesity drug landscape that is already crowded and moving fast:

Tirzepatide (Eli Lilly) is the current market leader in the dual-agonist category, with approved indications for both diabetes and obesity. Retatrutide is Lilly competing against itself—a triple agonist designed to supersede its own dual agonist.

Viking Therapeutics’ VK2735 completed enrollment in its Phase 3 VANQUISH-2 trial in March 2026, with results expected in Q3. VK2735 is a GLP-1/GIP dual agonist available in both injectable and oral formulations—the oral version showed 12.2% weight loss at 13 weeks in Phase 2.

Amgen’s MariTide and the emerging amylin agonist class (including Alveus Therapeutics’ ALV-200, backed by $197 million in Series A funding) represent the next wave: drugs that target different receptor systems entirely, potentially offering weight loss with better lean mass preservation.

The obesity drug market is no longer a one-molecule story. Retatrutide’s data will shape the next chapter. Retatrutide’s data will shape the next chapter. Retatrutide’s data will shape the next chapter. Retatrutide’s data will shape the next chapter. It’s a pipeline story, and retatrutide’s data—both the 28.7% efficacy and the 18% discontinuation rate—will shape how regulators, clinicians, and patients think about the risk-benefit tradeoff for the next generation of weight loss treatments.

What Peptidings Is Watching

The remaining seven Phase 3 readouts. TRIUMPH-4 was the first. The diabetes trials, the maintenance dosing studies, and any cardiovascular outcomes data will determine whether retatrutide’s profile holds up across populations and whether the discontinuation rate improves with different dosing strategies.

The FDA’s tolerability threshold. An 18% discontinuation rate at the top dose is not disqualifying, but it will generate questions. If Lilly pursues a tiered dosing approach—starting lower, titrating up, offering maintenance at submaximal doses—the tolerability picture could change substantially.

Head-to-head comparisons. The ultimate question isn’t whether retatrutide works—it clearly does—but whether the incremental weight loss over tirzepatide justifies the incremental side effect burden. That data doesn’t exist yet, and the market will demand it.

For the full evidence review on retatrutide, including mechanism of action, evidence tier, and the complete clinical trial landscape, see our retatrutide compound article.

For the full evidence review, see our retatrutide compound article. Compare with semaglutide and tirzepatide in our Weight Loss and Metabolic Health research hub.

Peptidings tracks the clinical pipeline for GLP-1 agonists and obesity therapeutics across our Weight Loss and Metabolic Health research hub. Every compound article includes evidence tier ratings, safety analysis, and Claims vs. Evidence evaluation.